Mitoxantrone and cyclophosphamide combination chemotherapy for the treatment of various canine malignancies.
Thirteen dogs with histopathologically confirmed malignancies were treated with mitoxantrone and cyclophosphamide combination therapy. One to four doses were administered at 21-day intervals. Recombinant human granulocyte colony-stimulating factor was administered to ameliorate myelosuppression in dogs with neutrophil nadirs less than 1,000/microl. While the protocol appears to be safe for use in tumor-bearing dogs, an advantage over mitoxantrone single-agent protocols in terms of tumor response was not demonstrated in this initial pilot study.
Henry
C J
CJ
Department of Veterinary Medicine and Surgery, University of Missouri-Columbia, 65211, USA.
Buss
M S
MS
Potter
K A
KA
Wardrop
K J
KJ
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D016896:Treatment Outcome
D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D008942:Mitoxantrone